Coherus Biosciences | CHRS - Ebitda


Coherus Biosciences reported $-43.33M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 3.69B 1.68B Mar/2026
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
ALKERMES USD 139.22M 58.96M Jun/2026
Alnylam Pharmaceuticals USD 245.34M 59.15M Jun/2026
Amarin USD 12.54M 28.57M Jun/2025
Amgen USD 3.86B 1.28B Mar/2026
Baxter International USD 309M 756M Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Coherus Biosciences USD -43.33M 4.7M Sep/2025
Eli Lilly USD 10.29B 1.86B Mar/2026
Fujifilm JPY 101.61B 48.31B Jun/2026
Gilead Sciences USD 3.51B 489M Mar/2026
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Merck USD -1.54B 7.84B Mar/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Pacira USD 48.67M 8.43M Jun/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
PTC Therapeutics USD 61.98M 132.97M Mar/2026
Regeneron Pharmaceuticals USD 1.66B 695.2M Jun/2026
Sarepta Therapeutics USD 375.48M 627.68M Mar/2026
Teva Pharmaceutical Industries USD 474M 581M Jun/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026
Xencor USD -34.63M 86.74M Jun/2026
Zoetis USD 939M 0 Mar/2026